Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide
Carl E Stafstrom
Section of Pediatric Neurology, Departments of Neurology and Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
Objective: This review summarizes the treatment of Lennox-Gastaut syndrome, an intractable epileptic encephalopathy of early childhood. In particular, the review focuses on rufinamide, a recently released anticonvulsant medication with reported effectiveness in this epilepsy syndrome.
Methods: A systematic literature search (PubMed) was performed to review the existing literature pertaining to the treatment of Lennox-Gastaut syndrome as well as studies involving rufinamide as an anticonvulsant medication.
Results: The published literature to date documents a beneficial effect of rufinamide on children over 4 years old with Lennox-Gastaut syndrome. Studies indicate a significant decrease in tonic and atonic seizure frequency as well as total seizure frequency compared to placebo-treated children. Rufinamide appears to be well tolerated and a safe medication, somnolence and vomiting being the most common side effects.
Conclusions: Rufinamide is a promising adjunctive therapy for Lennox-Gastaut syndrome, an intractable childhood epilepsy. To ensure its optimal effectiveness, clinicians must be familiar with the medication’s clinical response profile and potential for adverse effects.
Keywords: pediatric, epilepsy, epileptic encephalopathy, Lennox-Gastaut syndrome, rufinamide
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Readers of this article also read:
Multifunction hexagonal liquid-crystal containing modified surface TiO2 nanoparticles and terpinen-4-ol for controlled release
Manaia EB, Kaminski RCK, Oliveira AG, Corrêa MA, Chiavacci LA
Published Date: 22 January 2015
Thomsen RW, Sørensen HT
Published Date: 18 December 2014
Sex differences in the prediction of the effectiveness of paroxetine for patients with major depressive disorder identified using a receiver operating characteristic curve analysis for early response [Corrigendum]
Tomita T, Norio YF, Sato Y, Nakagami T, Tsuchimine S, Kaneda A, Kaneko S
Published Date: 5 June 2014
Thomes BE, Callaghan TA
Published Date: 25 July 2013
Effects of Arthro-7® in relieving symptoms of osteoarthritis with mild to moderate arthralgia [Corrigendum]
Xie Q, Zhou T, Yen L, Shariff M, Nguyen T, Kami K, Gu P, Liang L, Rao J, Shi R
Published Date: 16 May 2013
Lemon TI, Shah RD
Published Date: 7 May 2013
Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
Nielsen SA, McDonald MB, Majmudar PA
Published Date: 15 April 2013
Comparison with ancestral diets suggests dense acellular carbohydrates promote an inflammatory microbiota, and may be the primary dietary cause of leptin resistance and obesity
Published Date: 6 July 2012
Published Date: 18 August 2011
Difluprednate ophthalmic emulsion 0.05% (Durezol®) administered two times daily for managing ocular inflammation and pain following cataract surgery
Stephen Smith, Douglas Lorenz, James Peace, et al.
Published Date: 30 August 2010